<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073290</url>
  </required_header>
  <id_info>
    <org_study_id>PEARL trial</org_study_id>
    <secondary_id>2018-004323-37</secondary_id>
    <secondary_id>848017009</secondary_id>
    <nct_id>NCT04073290</nct_id>
  </id_info>
  <brief_title>Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose</brief_title>
  <acronym>PEARL</acronym>
  <official_title>Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with
      liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration
      as minimal HE (MHE), covert HE (grade I), or overt HE (OHE, grade II-IV). Liver cirrhosis is
      the most common cause of portal hypertension (PH). Patients who develop complications of PH,
      like variceal bleeding or refractory ascites, can benefit from a Transjugular Intrahepatic
      Portosystemic Shunt (TIPS) placement. Unfortunately, post-TIPS HE is a common and often
      severe complication. Incidence of new onset or worsening of HE after TIPS is approximately
      20-45%. Currently there is no strategy to prevent post-TIPS HE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the incidence of post-TIPS OHE within the first three months after
      prophylactic administration of lactulose and rifaximin versus placebo in patients who undergo
      Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement.

      Study design: A multicentre, randomized, placebo-controlled, double blind study.

      Study population: Adult consecutive patients undergoing elective TIPS placement (for
      refractory ascites or secondary prophylaxis in variceal bleeding) in all Dutch academic
      centres where TIPS procedures are performed: Amsterdam UMC, location Academic Medical Centre
      (AMC), Erasmus MC, Leiden University Medical Centre (LUMC), Maastricht University Medical
      Centre+ (MUMC+), Radboud University Medical Centre (Radboudumc), University Medical Centre
      Groningen (UMCG), and University Hospitals Leuven (UZ Leuven) in Belgium.

      Intervention: Rifaximin 550 milligram (mg) b.i.d. will be prescribed, in combination with a
      starting dose of 25 milliliter (mL) lactulose b.i.d. and further dependent on the amount of
      daily bowel movements, with the objective not to exceed more than two soft stools per day.
      Intervention will start 72 hours before TIPS placement, and will last till three months after
      TIPS placement. The control group will receive placebo in combination with lactulose (as
      described above).

      Main study parameters/endpoints: Primary endpoint is the development of OHE within three
      months after TIPS placement determined by the West Haven criteria. Secondary endpoints are 90
      day mortality; development of a second episode of OHE within the first three months;
      development of OHE in the period between three and twelve months after TIPS placement;
      development of MHE between TIPS placement and twelve months after placement; the increase of
      the psychometric hepatic encephalopathy score (PHES) and simplified one minute animal naming
      test (S-ANT1) compared to baseline. Differences in molecular composition of peripheral /
      portal blood samples at TIPS placement. Furthermore, quality of life will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post-TIPS Hepatic Encephalopathy</measure>
    <time_frame>First 3 months after TIPS placement</time_frame>
    <description>post-TIPS Hepatic Encephalopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant free survival</measure>
    <time_frame>One year</time_frame>
    <description>Transplant free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to development of post-TIPS HE episode(s)</measure>
    <time_frame>One year</time_frame>
    <description>time to development of post-TIPS HE episode(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of a second episode of post-TIPS HE</measure>
    <time_frame>3 months</time_frame>
    <description>development of a second episode of post-TIPS HE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of post-TIPS HE between 3-12 months after TIPS placement</measure>
    <time_frame>3-12 months</time_frame>
    <description>development of post-TIPS HE between 3-12 months after TIPS placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Psychometric Hepatic Encephalopathy Score (PHES) compared to baseline</measure>
    <time_frame>One year</time_frame>
    <description>change in total PHES score compared to baseline (range -15 - +5) a lower score is a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in one-minute animal naming test compared to baseline</measure>
    <time_frame>One year</time_frame>
    <description>change in one-minute animal naming test compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences in molecular composition of peripheral / portal blood samples</measure>
    <time_frame>One year</time_frame>
    <description>differences in molecular composition of peripheral / portal blood samples at TIPS placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences in molecular composition of peripheral blood samples</measure>
    <time_frame>One year</time_frame>
    <description>differences in molecular composition of peripheral blood samples at baseline, compared to day 10 post-TIPS, week 4, week 12, and week 52;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health related Quality of life</measure>
    <time_frame>One year</time_frame>
    <description>Health related Quality of life, measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease rrelated Quality of life</measure>
    <time_frame>One year</time_frame>
    <description>Health related Quality of life, Liver Disease Symptom Index (LDSI) 2.0 questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>One year</time_frame>
    <description>Cost-effectiveness, measured by a combined questionnaire, based on institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ)/Medical Consumption Questionnaire (iMCQ)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Portal Hypertension</condition>
  <condition>Liver Diseases</condition>
  <condition>Pathological Processes</condition>
  <arm_group>
    <arm_group_label>Rifaximin and lactulose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifaximin 550 milligram b.i.d. combined with lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and lactulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo b.i.d. combined with lactulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin 550 milligram Oral Tablet [XIFAXAN]</intervention_name>
    <description>Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS</description>
    <arm_group_label>Rifaximin and lactulose</arm_group_label>
    <other_name>TARGAXAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS</description>
    <arm_group_label>Placebo and lactulose</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose 667 milligram/milliliter Oral Solution</intervention_name>
    <description>Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS</description>
    <arm_group_label>Placebo and lactulose</arm_group_label>
    <arm_group_label>Rifaximin and lactulose</arm_group_label>
    <other_name>Lactulose syrup</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Elective TIPS placement for refractory ascites or recurrent variceal bleeding:

             Recurrent tense ascites and one or more of the following criteria:

             i. Not responding to the maximal dose of diuretics (400 milligram spironolactone and
             160 milligram furosemide).

             ii. Kidney insufficiency (Creatinine &gt; 135 umol/L) induced by diuretics. iii.
             Electrolyte disturbances (Sodium &lt; 125 mmol/L, Potassium &gt; 5.5 mmol/L) induced by
             diuretics.

             iv. Not tolerating higher dose of diuretics (e.g. because of subjective side effects
             like muscle cramps).

             Recurrent variceal bleeding, not responsive to treatment with endoscopic band ligation
             and beta-blockers, with a high risk of failure of endoscopic treatment:

             i. Patients with a variceal bleeding and Child-Pugh C (10-13 points) cirrhosis or ii.
             Patients with a variceal bleeding, Child-Pugh B and an active bleeding during
             endoscopy

          2. Age ≥18 years

          3. Confirmed liver cirrhosis as documented by liver biopsy, elastography (e.g. Fibroscan)
             or combination of usual radiological and biochemical criteria.

          4. Signed informed consent

        Exclusion Criteria:

          1. Any absolute contraindications for TIPS placement

          2. Use of ciclosporin

          3. Life-threatening variceal bleeding with emergency TIPS placement which can not be
             delayed 72 hours

          4. Age &gt; 80 years

          5. Non-cirrhotic portal hypertension

          6. Portal vein thrombosis

          7. History of OHE not induced by Spontaneous bacterial peritonitis (SBP) or
             gastrointestinal bleed

          8. Current or recent (&lt;3 months) use of rifaximin

          9. Overt neurologic diseases such as Alzheimer's disease, Parkinson's disease

         10. Pregnant or breastfeeding women

         11. Patients refusing or unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Takkenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koos de Wit, MD</last_name>
    <phone>0031-20-5668468</phone>
    <email>leverresearch@amc.uva.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Nevens, prof. dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Takkenberg, dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Dr. Bart Takkenberg</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <keyword>Rifaximin</keyword>
  <keyword>Lactulose</keyword>
  <keyword>post-TIPS HE</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

